激素非依赖性前列腺癌细胞免疫水平变化及“扶正抑瘤法”干预的研究
|
摘要
前列腺癌是泌尿外科最常见的肿瘤之一,我国近年来发病率不断上升,已跃居泌尿生殖系恶性肿瘤的第3位。内分泌治疗是前列腺癌目前最主要的治疗方法,但现有研究表明,经过中位时间14～30个月后,大部患者经治疗后最终都转为激素非依赖性前列腺癌。因此,寻求有效治疗激素非依赖性前列腺癌的途径,以提高激素非依赖性前列腺癌患者的生存质量、延长其生存期,成为目前及今后一个阶段医学迫切需要解决的问题。中医药是防治肿瘤的有效方法之一,众多研究抗肿瘤疗效及机制的结果都表明,调节患者免疫功能,使患者重建免疫功能平衡或提高患者免疫功能,从而有效发挥免疫的抗肿瘤机制,是其最重要的机理之一。在前期对晚期前列腺癌病因病机、辨证分型及运用中西医结合扶正以抑瘤的方法治疗晚期前列腺癌临床证实有效的研究基础上,通过专家意见征询总结,再次拟定中西医结合前列腺癌的诊疗工作手册,规范本院前列腺癌诊疗工作;对激素非依赖性前列腺癌的病因病机进行进一步总结,认识到激素非依赖性前列腺癌的病机以虚虚为本,故导师陈志强教授提出扶正以抑瘤理论,治疗上以补虚为主、祛邪为辅,在临床中取得一定疗效。并通过实验研究方面以扶正抑瘤法组方的含药血清对PC-3细胞进行体外实验,结果显示以扶正抑瘤法组方的含药血清能抑制人前列腺癌PC-3细胞的增殖,且呈剂量、浓度依赖性,其抗肿瘤活性可能与诱导肿瘤细胞凋亡有关;从细胞学角度再次证实扶正抑瘤法对激素非依赖性前列腺癌细胞具有抑制其增殖及诱导癌细胞凋亡的作用。在此基础上,本研究拟探讨激素非依赖性前列腺癌与细胞免疫水平的相关性,并观察扶正抑瘤法治疗激素非依赖性前列腺癌的临床疗效及可能的作用机理,从而为中西医结合有效治疗激素非依赖性前列腺癌提供临床依据。
目的
探讨激素非依赖性前列腺癌细胞免疫水平变化,评价扶正抑瘤法治疗激素非依赖性前列腺癌的疗效及对其细胞免疫水平影响。
方法
以36例激素依赖性前列腺癌患者作为研究对象,39例激素依赖期前列腺癌患者作为研究对照组。使用流式细胞仪技术(FCM)测定其外周血T淋巴细胞亚群(CD_3~+、CD_4~+、CD_8~+)及NK细胞(CD_((16+56))~+)水平变化。同时按治疗方法差异自然入选分组的队列研究方法,将36例激素依赖性前列腺癌患者又分为治疗组及对照组,对照组予以现行“前列腺癌诊断治疗指南”二线内分泌治疗,治疗组在二线内分泌治疗基础上予以患者扶正抑瘤法中医药治疗,均在治疗前后记录患者临床症状变化、测定其血清前列腺特异性抗原(PSA)变化、B超检查局部病灶的变化、行Karnofsky行为量表评分;治疗组及对照组均在治疗3个月后再次取外周血以FCM测定其CD_3~+、CD_4~+、CD_4~+及CD_(916+56))~+水平。
结果
治疗前激素非依赖性前列腺癌患者CD_3~+T、CD_~+T及CD_8~+T水平均明显下降,与前列腺癌激素依赖期患者(对照组)比较差异有统计学意义(P＜0.05)。CD_((16+56))~+N水平亦下降明显,与对照组比较差异有统计学意义。但CD_4~+/CD_8~+比值上升,与对照组比较差异无统计学意义。
经治疗后,在临床症状改善方面:治疗组临床有效率为78.94%,对照组有效率为62.5%。而在PSA水平控制方面:治疗组PSA值下降＞50%者14例,有效率为73.68%;PSA持续上升者2例,对照组PSA值下降＞50%者7例,有效率为43.75%;Ridit分析均示差异有统计学意义(P＜0.05)。在生存质量评分方面:治疗组的Karnofsky评分在治疗后与治疗前比较差异有统计学意义(P＜0.01)。虽然对照组虽经治疗后Karnofsky评分稍升高,但前后对比差异无统计学意义。
在细胞免疫水平方面:治疗组在CD_3~+及CD_4~+水平在治疗前后比较差异有统计学意义(P＜0.05),对照组的CD_3~+、CD_4~+水平在治疗前后对比均无统计学意义。虽然治疗组CD8+水平治疗后较治疗前轻微下调,而对照组CD_8~+水平治疗后较治疗前轻微上调,治疗前后对比差异均无统计学意义。CD_4~+/CD_8~+T比值治疗组经治疗后明显提高,前后对比差异有统计学意义(P＜0.05);而对照组的CD_4~+/CD_8~+T比值在治疗前后对比差异无统计学意义。治疗组的CD_((16+56))~+N水平经治疗后上调,在治疗前后比较差异有统计学意义(P＜0.05)。而对照组的CD_((16+56))~+N水平在治疗前后对比无统计学意义,经治疗后CD_((16+56))~+N水平反而下降。
结论
激素非依赖性前列腺癌患者整体CD_3~+、CD_4~+、CD_8~+及CD_((16+56))~+水平下降;扶正抑瘤法能有效改善激素非依赖性前列腺癌患者临床症状,控制PSA水平,明显改善患者生存质量;经扶正抑瘤法治疗后,治疗组患者CD_3~+、CD_4~+及CD_((16+56))~+水平明显上调。提示激素非依赖性前列腺癌癌患者细胞免疫水平明显下降或受抑制、紊乱,扶正抑瘤法能有效治疗激素非依赖性前列腺癌,作用机制可能与调节患者细胞免疫水平有关。
Prostate cancer is one of the most common urology tumor,in recent years, the incidence of prostate cancer is rising continuously in China,and now it has become the third common tumors of Urogenital.Endocrine therapy for prostate cancer is currently the main treatment,but now studies have shown that after amedian survival time of 14 to 30 months,most patients eventually are transformed to hormone independent prostate cancer.Therefore,it is an urgent problem need to be resolved that how to find effective treatment for hormone independent prostate cancer to enhancing quality of life of the patients and prolonging their survival time.Traitional Chinese Medicine(TCM) is an effective way to prevent and cure cancer,one of the important anti-tumor mechanisms is found that to regulate the immune function of patients,so that to reconstruct the immune balance function of patients or enhance the immune function.According to TCM theory,hormone independent prostate cancer is an extreme deficient disease,so my tutor professor Chen Zhiqiang proposes the theory of Fuzheng aiming to Yiliu,point to treating patients by tonifying deficient symptoms,and it had gained fine effects in clinical.This study is to investigate the relevance between hormone independent prostate cancer and cell-mediated immunity,and to observe the clinical efficacy and possible mechanism of Fuzhengyiliu therapy for hormone independent prostate
cancer,therefore to provide clinical basis for the effective treatment of hormone-dependent of prostate combining TCM with western medicine.
Objective
To investigate the changes of cell-mediated immunity of hormone independent prostate cancer,evaluate the clinical efficacy of patients treated by Fuzhengyiliu therapy and its impact on the level of cell-mediated immunity.
Methods
36 cases of patients with hormone independent prostate cancer were selected to be studyed,and 39 cases with prostate cancer in hormone dependent period were selected as control study group,T lymphocyte subsets(CD_3~+、CD_4~+、CD_8~+) and Nature Killer cell(CD_((16+56))~-+) activities in peripheral blood of all patients were detected by Flow cytometry(FCM).At the same time,36 cases of patients with hormone independent prostate cancer were divided into two groups(treatment group and control group)according to different treatment methods in the light of cohort study method.The control group was treated by the current second-line endocrine therapy,and the treatment group was treated by the second-line hormonal therapy and Fuzheng yiliu therapy.Before and after treatment,the changes of clinical symptoms,peripheral serum prostate specific antigen(pSA) and the changes of local lesions of all patients were detected,and also all were gived a mark of the Karnofsky Scale score:After treating for three months,the treatment group and control group were decected the level of peripheral blood CD_3~+、CD_4~+、CD_8~+ and CD_((16+56))~+ again.
Results
As compared with the control study group(the patients with hormone dependent period prostate cancer),the level of CD_3~+T、CD_4~+T and CD_8~+T were significantly decreased before treating in hormone independent prostate cancer patients,and the difference was statistically significant(P＜0.05). And the level of CD_((16+56))~+N of hormone independent prostate cancer also decreased significantly when compared with the control study group.However,the ratio of CD_8~+/CD_8~+ increased,the difference was not statistically significant compared with the control study group.
After the treatment,The effective rate of the Fuzhengyiliu therapy group was 78.94%,and the control group was 56.25%in clinical symptoms,In controlling of PSA levels,there were 14 cases who had been found decreased more than 50%in Fuzhengyiliu therapy group,and 2 cases continued to rise; And there were 7 cases decreased by more than 50%in control group;That is to say,the effective rate of Fuzhengyiliu therapy group was 73.68%and the control group was 43.75%in pSA levels,and there was significant difference in statistics between Fuzhengyiliu therapy group and control group according to Ridit analysis method(P<0.05).Furthermore,on quality of life scored by the Karnofsky Scale score method,it also has significant statistical difference between the pro-treatment and the pre-treatment of the Fuzhengyiliu therapy group(P<0.01).After the treatment,the Karnofsky score of the control group slightly increased,however,there was no statistic difference when comparing patients after treatment with pre-treatment patients.
In the cell-mediated immunity,the CD_3~+ and CD_8~+ level in Fuzhengyiliu therapy group showed significant statistic differences when after treatment patients compared with before treatment(P<0.05),but no significant difference was found in the control group of those index.The CD_8~+ level in the Fuzhengyiliu therapy group decreased slightly after the treatment,while increased slightly in the control group after the treatment,however,there was no statistic difference in both of them.The ratio of CD_4~+/CD_8~+ T in the Fuzhengyiliu therapy group increased distinctly after the treatment(P<0.05),but those in the control group had no obvious difference. The level of CD_((16+56))~+ in the Fuzhengyiliu therapy group had increased significantly after treatment(P<0.05),while that in the control group decreased,and there was no obvious difference comparing patients before treatment with those after treatment.
Conclusion
The level of CD_3~+、CD_4~+、CD_8~+ and CD_((16+56))~+ were decreased overall in hormone independent prostate cancer patients;Fuzhengyiliu therapy could improve the clinical symptoms effectively,control the level of pSA,and evidently improve the quality of life of the patients;After treated by Fuzhengyiliu therapy,the level of CD_3~+,CD_4~+ and CD_((16+56))~+ were significantly raised.It is suggested that there is a dysfunction condition mainly suppressed or significantly decreased in cell-mediated immunity function of patients with hormone independent prostate cancer;Fuzheng Yiliu therapy could treat the patients effectively, probably by adjusting the level of cell-mediated immunity of the patients.
目的
探讨激素非依赖性前列腺癌细胞免疫水平变化,评价扶正抑瘤法治疗激素非依赖性前列腺癌的疗效及对其细胞免疫水平影响。
方法
以36例激素依赖性前列腺癌患者作为研究对象,39例激素依赖期前列腺癌患者作为研究对照组。使用流式细胞仪技术(FCM)测定其外周血T淋巴细胞亚群(CD_3~+、CD_4~+、CD_8~+)及NK细胞(CD_((16+56))~+)水平变化。同时按治疗方法差异自然入选分组的队列研究方法,将36例激素依赖性前列腺癌患者又分为治疗组及对照组,对照组予以现行“前列腺癌诊断治疗指南”二线内分泌治疗,治疗组在二线内分泌治疗基础上予以患者扶正抑瘤法中医药治疗,均在治疗前后记录患者临床症状变化、测定其血清前列腺特异性抗原(PSA)变化、B超检查局部病灶的变化、行Karnofsky行为量表评分;治疗组及对照组均在治疗3个月后再次取外周血以FCM测定其CD_3~+、CD_4~+、CD_4~+及CD_(916+56))~+水平。
结果
治疗前激素非依赖性前列腺癌患者CD_3~+T、CD_~+T及CD_8~+T水平均明显下降,与前列腺癌激素依赖期患者(对照组)比较差异有统计学意义(P＜0.05)。CD_((16+56))~+N水平亦下降明显,与对照组比较差异有统计学意义。但CD_4~+/CD_8~+比值上升,与对照组比较差异无统计学意义。
经治疗后,在临床症状改善方面:治疗组临床有效率为78.94%,对照组有效率为62.5%。而在PSA水平控制方面:治疗组PSA值下降＞50%者14例,有效率为73.68%;PSA持续上升者2例,对照组PSA值下降＞50%者7例,有效率为43.75%;Ridit分析均示差异有统计学意义(P＜0.05)。在生存质量评分方面:治疗组的Karnofsky评分在治疗后与治疗前比较差异有统计学意义(P＜0.01)。虽然对照组虽经治疗后Karnofsky评分稍升高,但前后对比差异无统计学意义。
在细胞免疫水平方面:治疗组在CD_3~+及CD_4~+水平在治疗前后比较差异有统计学意义(P＜0.05),对照组的CD_3~+、CD_4~+水平在治疗前后对比均无统计学意义。虽然治疗组CD8+水平治疗后较治疗前轻微下调,而对照组CD_8~+水平治疗后较治疗前轻微上调,治疗前后对比差异均无统计学意义。CD_4~+/CD_8~+T比值治疗组经治疗后明显提高,前后对比差异有统计学意义(P＜0.05);而对照组的CD_4~+/CD_8~+T比值在治疗前后对比差异无统计学意义。治疗组的CD_((16+56))~+N水平经治疗后上调,在治疗前后比较差异有统计学意义(P＜0.05)。而对照组的CD_((16+56))~+N水平在治疗前后对比无统计学意义,经治疗后CD_((16+56))~+N水平反而下降。
结论
激素非依赖性前列腺癌患者整体CD_3~+、CD_4~+、CD_8~+及CD_((16+56))~+水平下降;扶正抑瘤法能有效改善激素非依赖性前列腺癌患者临床症状,控制PSA水平,明显改善患者生存质量;经扶正抑瘤法治疗后,治疗组患者CD_3~+、CD_4~+及CD_((16+56))~+水平明显上调。提示激素非依赖性前列腺癌癌患者细胞免疫水平明显下降或受抑制、紊乱,扶正抑瘤法能有效治疗激素非依赖性前列腺癌,作用机制可能与调节患者细胞免疫水平有关。
Prostate cancer is one of the most common urology tumor,in recent years, the incidence of prostate cancer is rising continuously in China,and now it has become the third common tumors of Urogenital.Endocrine therapy for prostate cancer is currently the main treatment,but now studies have shown that after amedian survival time of 14 to 30 months,most patients eventually are transformed to hormone independent prostate cancer.Therefore,it is an urgent problem need to be resolved that how to find effective treatment for hormone independent prostate cancer to enhancing quality of life of the patients and prolonging their survival time.Traitional Chinese Medicine(TCM) is an effective way to prevent and cure cancer,one of the important anti-tumor mechanisms is found that to regulate the immune function of patients,so that to reconstruct the immune balance function of patients or enhance the immune function.According to TCM theory,hormone independent prostate cancer is an extreme deficient disease,so my tutor professor Chen Zhiqiang proposes the theory of Fuzheng aiming to Yiliu,point to treating patients by tonifying deficient symptoms,and it had gained fine effects in clinical.This study is to investigate the relevance between hormone independent prostate cancer and cell-mediated immunity,and to observe the clinical efficacy and possible mechanism of Fuzhengyiliu therapy for hormone independent prostate
cancer,therefore to provide clinical basis for the effective treatment of hormone-dependent of prostate combining TCM with western medicine.
Objective
To investigate the changes of cell-mediated immunity of hormone independent prostate cancer,evaluate the clinical efficacy of patients treated by Fuzhengyiliu therapy and its impact on the level of cell-mediated immunity.
Methods
36 cases of patients with hormone independent prostate cancer were selected to be studyed,and 39 cases with prostate cancer in hormone dependent period were selected as control study group,T lymphocyte subsets(CD_3~+、CD_4~+、CD_8~+) and Nature Killer cell(CD_((16+56))~-+) activities in peripheral blood of all patients were detected by Flow cytometry(FCM).At the same time,36 cases of patients with hormone independent prostate cancer were divided into two groups(treatment group and control group)according to different treatment methods in the light of cohort study method.The control group was treated by the current second-line endocrine therapy,and the treatment group was treated by the second-line hormonal therapy and Fuzheng yiliu therapy.Before and after treatment,the changes of clinical symptoms,peripheral serum prostate specific antigen(pSA) and the changes of local lesions of all patients were detected,and also all were gived a mark of the Karnofsky Scale score:After treating for three months,the treatment group and control group were decected the level of peripheral blood CD_3~+、CD_4~+、CD_8~+ and CD_((16+56))~+ again.
Results
As compared with the control study group(the patients with hormone dependent period prostate cancer),the level of CD_3~+T、CD_4~+T and CD_8~+T were significantly decreased before treating in hormone independent prostate cancer patients,and the difference was statistically significant(P＜0.05). And the level of CD_((16+56))~+N of hormone independent prostate cancer also decreased significantly when compared with the control study group.However,the ratio of CD_8~+/CD_8~+ increased,the difference was not statistically significant compared with the control study group.
After the treatment,The effective rate of the Fuzhengyiliu therapy group was 78.94%,and the control group was 56.25%in clinical symptoms,In controlling of PSA levels,there were 14 cases who had been found decreased more than 50%in Fuzhengyiliu therapy group,and 2 cases continued to rise; And there were 7 cases decreased by more than 50%in control group;That is to say,the effective rate of Fuzhengyiliu therapy group was 73.68%and the control group was 43.75%in pSA levels,and there was significant difference in statistics between Fuzhengyiliu therapy group and control group according to Ridit analysis method(P<0.05).Furthermore,on quality of life scored by the Karnofsky Scale score method,it also has significant statistical difference between the pro-treatment and the pre-treatment of the Fuzhengyiliu therapy group(P<0.01).After the treatment,the Karnofsky score of the control group slightly increased,however,there was no statistic difference when comparing patients after treatment with pre-treatment patients.
In the cell-mediated immunity,the CD_3~+ and CD_8~+ level in Fuzhengyiliu therapy group showed significant statistic differences when after treatment patients compared with before treatment(P<0.05),but no significant difference was found in the control group of those index.The CD_8~+ level in the Fuzhengyiliu therapy group decreased slightly after the treatment,while increased slightly in the control group after the treatment,however,there was no statistic difference in both of them.The ratio of CD_4~+/CD_8~+ T in the Fuzhengyiliu therapy group increased distinctly after the treatment(P<0.05),but those in the control group had no obvious difference. The level of CD_((16+56))~+ in the Fuzhengyiliu therapy group had increased significantly after treatment(P<0.05),while that in the control group decreased,and there was no obvious difference comparing patients before treatment with those after treatment.
Conclusion
The level of CD_3~+、CD_4~+、CD_8~+ and CD_((16+56))~+ were decreased overall in hormone independent prostate cancer patients;Fuzhengyiliu therapy could improve the clinical symptoms effectively,control the level of pSA,and evidently improve the quality of life of the patients;After treated by Fuzhengyiliu therapy,the level of CD_3~+,CD_4~+ and CD_((16+56))~+ were significantly raised.It is suggested that there is a dysfunction condition mainly suppressed or significantly decreased in cell-mediated immunity function of patients with hormone independent prostate cancer;Fuzheng Yiliu therapy could treat the patients effectively, probably by adjusting the level of cell-mediated immunity of the patients.
引文
[1]江勤康,戴颖秀.上海市杨浦区1980-1999年前列腺癌流行趋势分析[J].中国肿瘤.2002,11(5):263-265.
[2]刘耀庭,李秀霞,程伟,等.泌尿外科肿瘤发病情况的变化[J].临床泌尿外科杂志.1997,12(1):47-50.
[3]Grossfeld GD,Stier DM,Flanders SC,et al.Use of second treatment following definitive local therapy for prostate cancer:data from the caPSURE database[J].J Urokl.1998,160:1398-1404.
[4]Luyao GL,Potosky AL,Albertsen PC,et al.Follow-up prostate cancer treatments after radicalprostatectomy:a population-based study[J].J Natl Cancer Inst.1996.88:166-173.
[5]BoTr S R J.Management of recurrent disease after radical prostatectomy[J].Prostate Cancer Prostatic Dis.2004,7:211-216.
16]Wingo pA,Cardinez CJ,Landis SH,et al.Long-term trends in cancer mortality in the United States,1930-1998[J].Cancer.2003,97(12 Suppl):3133-3275.
[7]Ceraline J,Cruchant MD,Erdmann E,et al.Constitutive activation of the androgen receptor by a point mutation in the hinge region:a new mechanism for androgen-independent growth in prostate cancer[J].Int J Cancer.2004,108:152-157.
[8]Bubendof L,Kononen J,Koivisto p,et al.Survey of gene amplification during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays[J].Cancer Res.1999,59:803-806.
[9]Edwards J,Krishna N S,Grigor K M,et al Androgen receptor gene amplication and protein expression in hormone refractory prostate cancer[J].Br J cancer.2003,89:552-526.
[10]Kang H Y,Yeh S,Fujimoto N,et al.Cloning and characterization of human prostate coactivator ARA54,a novel protein that associates with the androgen receptor[J].J Biol Chem.1999,274:8570-8576.
[11]Miyamoto H,Yeh S,Wilding G,et al.promotion of agonist activity of antiandrogens by the of androgen receptor coactivator,ARA70.in human prostate cancer DU145 cells[J].Proc Nail Acad Sci USA.1998,95:7379-384.
[12]Yeh S,Lin HK,Kang HY,etal.From HER2/Neu signal cascade to androgen receptor an dits coactivator:a novel pathway by induction of androgen target genes through MAp kinase in prostate cancer cells[J].Proc Nail Acad Sci USA.1999,96:5458-5463.
[13]Gao X,Loggie B W,Nawaz Z.The roles of sex steroid receptor coregulators in cancer[J].Mol Cancer.2004,14:1-7.
[14]Smith C L,O Malley B W.Coregulator function:a key to understanding tissue specificity of selective receptor modulators[J].Endo Rev.2004,25:45-71.
[15]Sadar MD.Androgen-independent induction of prostate specifican tigen gene expression via cross-talk between the androgenreceptor and protein kinase A signal transduction pathways[J].J Biol Chem.1999,274:7777-7783.
[16]Yang L,Wang L,Lin HK,et al.Interleukin-6 diferentially regulat-es androgen receptor tansactivation via pI3K-Akt,STAT3 and MApK,three distinct signal pathways in prostate cancer cells[J].Biochem Biophys Res Commun.2003,305:462-469.
[17]Culig Z,Hohisch A,Cronauer M V,et al.Regulation of prostatic growth and function by peptide growth factors[J].Prostate.1996,28:392-405.
[18]Tan J,Sharief Y,Hamil K G,et al.Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCap cells[J].Mol Endocrinol.1997,11(4):450-459.
[19]王建功,闫天中.皮质醇与雄激素非依赖前列腺癌的关系[J].实用医药杂志.2004,21:595-596.
[20]Cofey RN,Watson RW,O Neill AJ,et al.Androgen-mediatedresistance to apoptosis[J].prostate,2002.53:300-309.
[21]Lip.Nicosia SV.Bai W.Antagonism between pTEN/MMAC1/TEp-1 and androgen receptor in growth and apoptosis of prostatic cancer cells[J].J Biol Chem,2001,276:20444-20450.
[22]Jaggi M,Rao pS,Smith DJ,et al.protein kinase Cμ is down-regulated in androgen-independent prostate cancer[J].Biochem Biophys Res Commun.2003,307:254-260.
[23]Halkidou K,Gaughan L,Cook S,etal.Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer[J].Prostate,2004,59:177-189.
[24]park J J,Irvine R A,Buchanan G,et al.Breast cancer susceptibility gene 1(BRCA1) is a coactivator of the androgen receptor[J].Cancer Res.2000,60:5946.
[25]Ryan CJ,Small EJ.Role of secondary hormonal therapy in the management of recurrent disease[J].Urology.2003,62(Suppl 6B):87-94.
[26]孙忠全 钱伟庆 宋建达.比卡鲁胺治疗雄激素非依赖性前列腺癌.中国癌症杂志[J].2006,16(2):158-159.
[27]Kelly WK,Scher HI.prostate specific antigen decline after antiandrogen withdrawal syndrome[J].J Urol.1993,149:607-609.
[28]华立新 吴宏飞 眭元庚,等.比卡鲁胺治疗激素抵抗性前列腺癌[J].中华泌尿外科杂志.2005,26(6).383-385.
[29]Kucuk O,Fisher E,Moinpour CM,et al.phase Ⅱ trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy hormonal therapy failed:a Southwest Oncology Group Study(SWOG92 35)[J].Urol.2001,58(1):53-58.
[30]OH WK,Kantoff pW.Management of hormone refractory prostate cancer:current standards and future prospects[J].J Uroi.1998,160(4):1220-1229.
[31]Miyake H,Hara I,Eto H.Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone refractory prostate cancer[J].BJU Int.2005,96(6):791-795.
[32]Graft JR.Emerging targets in the AKT pathway for treatment of androgen independent prostatic adenocarcinoma[J].Expert Opin rher Targets.2002,6(1):103-113.
[33]Yang F,Fuxhorn Jh,Ressler SJ.Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis[J].Cancer Res.2005,65(19):8887-8895.
[34]paramita M Ghosh,Shazli N Malik,Roble G Bedolla,et al.Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocrine Related[J].Cancer,2005,12:119-134.
[35]Smith DC,Redman BG,Flaherty LE,et al.A phase I1 trial of oral diethyl stilbesterol asasecond line hormonal agent in advanced prostate cancer[J].Urology.1998.52:257-260.
[36]Siddiqui K,Abbas F,Biyabani SR,et al.Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer[J].J pak Med Assoc,2004.54:445-447.
[37]孙忠全,钱伟庆,宋建达.己烯雌酚治疗雄激素非依赖性前列腺癌12例疗效分析[J].中华外科杂.2006,44(18).1265-1266.
[38]曹野,王进,聂勇,等.经泵动脉灌注抗癌药治疗雄激素非依赖性前列腺癌的疗效评价.介入放射学杂志.2008,17(9).641-644.
[39]Ronald DW,Mario AE,Ian T,et al.A multicenter comparionof docetaxel given weekly or every three weeks prednisone with mitoxantrone prednisone in patients with hormone-refractory prostate cancer:Study TAX-327[J].ASCO Abs,2004.
[40]Serafini AN,Houstion SJ,Resche I et al:palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double blind placebo controlled clinical trial[J].J Clin Oncol.1998,16:1574-1581.
[41]Mikata K,Uemura H,Ohuchi H,et al.Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene:gene transfer by electroporation [J].Mol Cancer Ther.2002,1(4):247-252.
[42]Huang S.Houghton pJ.Targeting m1UR signaling for cancer therapy[J].Curt Opin Pharmacol.2003,3:371-377.
[43]Sandra L,Krueckl,Robert A,et al.Increased Insulin-Like Growth Factor Ⅰ Receptor Expression and Signaling Are Components of Androgen- Independent progression in a Lineage-Derived prostate Cancer progression Model[J].Cancer Research.2004,64:8620-8629.
[44]padley RJ,Dixon DB,Wu Wong JR.Effect of castration on endothelin receptors[J].Clin Sci(Lond).2002,103(Suppl 48):442S-445S.
[45]高江平,洪宝发.雄激素非依赖性前列腺癌的治疗策略[J].中华泌尿外科杂志.2005,26(4):286-287.
[46]Emil A.Tanagho,Jack W.McAninch.Smiths General Urology 16e[M].Mc Graw-Hill Companies,Inc.2004.
[47]Hahne M,Rimoldi D,Schroter M,et al.Melanoma cell expression of Fas(Apo-1/CD95) ligand:implications for tumor immune escape[J].Science.1996,274(5291):1363.
[48]pandha,Hardev S,Menard S,et al.dendritic cell immunotherapy for urological cancers using cryopreserved allogenein tumor lysate-pulsed cell[J].BJU International.2004,94(3):412.
[49]Uyl-de Groot CA,Vermorken JB,Hanna MG Jr,et al.Immunotherapy with autologous tumor cell BCG vaccine in patients with colon cancer:a prospective study of medical and economic benefits[J].Vaccine.2005,23(17-18):2379-2387.
[50]Jocham D,Richter A,Hoffmann L,et al.Auvant autologous renal tumo- ur cell vaccine and risk of tumour progression in patients with renal cell carcinoma after radical nephrectomy:phase Ⅲ,randomised controlled trial[J].Lancet.2004,363(9409):594-599.
[51]Nemunaitis J,Nemunaitis J.A review of vaccine clinical trials for- nonsmall cell lung cancer[J].Expert Opin Biol Ther.2007,7(1):89-102.
[52]孙丽斌,张积仁,胡喜钢.异种抗原免疫序贯瘤内注射对肿瘤浸润淋巴细胞的影响[J].广东医学.2009,30(1):54-56.
[53]齐士勇,王萌,徐勇.前列腺癌组织中树突状细胞的变化及以此为基础的免疫治疗[J].中华男科学杂志.2007.5(13):453-456.
[54]丘少鹏,陈辉熔,邓春华,等.前列腺癌肿瘤微环境树突状细胞与T细胞免疫的关系[J].中山医科大学学报.2002,23(2 J:127-128,131.
[55]Mu LJ,Kyte JA,Kvalheim G,et al.Immunotherapy with allotumour mRNA.transfected dendritic cells in androgen-resistant prostate cancer patients[J].Br J Cancer.2005,93(7):749-56.
[56]Su Z,Dannull J,Yang BK,et al.Telomerase mRNA transfected dendritic cells stimulate antigen:specific CD8 and CD4 T cell responses in patients with metastatic prostate cancer[J].J Immunol.2005,174(6):3798-3807.
[57]Dreicer R.See W.A,Klein E.A.phase Ⅱ trial of GM-CSF in advanced prostate cancer[J].Invest.New Drugs.2001,19:261-265.
[58]Rini BI.Weinberg V,Bok R,el al.prostate-specific antigen kinetic as a measure of granulocyte macrophage colony stimulating factor with progression of prostate cancer[J].J Clin Oncol.2003,21:99-I05.
[59]Trudel S,Trachtenberg J,Toi A,et al.A phase Ⅰ trial adenovector-mediated delivery of interleukin-2(AdIL-2) in high-risk localized prostate cancer[J].Cancer Gene Ther.2003,10(10):755-763.
[60]Simons JW,Sacks N.Granulocyte-macrophage colony-stimularing factor transduced allogeneie cancer cellular immunotherapy:the GVAX vaccine for prostate cancer[J].Urol Oncol.2006,24(5):419-424.
[61]郁仁存.中医药防治肿瘤的作用和展望[J].中国中西医结合杂志.2007,27(5):389-390.
[62]何光星,刘洁,王笳,等.中医药抗肿瘤作用机理研究现状[J].2008.26(8):47-50.
[63]胡艳,曹洋,易华,等.仙鱼汤对Lewis肺癌荷瘤小鼠免疫功能的影响[J].广州中医药大学学报.2008,25(6)522-524,527.
[64]沈旭华,陈长勋.新云芝糖肽对S180荷瘤小鼠环磷酰胺化疗的增效减毒作用[J].肿瘤.2008,28(7):572-576.
[65]侯冰宗,舒晓春,周少朋,等.中药艾迪注射液对大肠癌术后机体免疫功能的影响[J].第四军医大学学报.2008,29(10):933-935.
[66]万华,吴雪卿,董佳容,等.“乳癌术后方”抗高转移小鼠乳腺癌作用机制的研 究[J].肿瘤.2007,27(9).691-693,709.
[67]王琪,程德春,王磊.川芎嚎对荷瘤鼠化疗后免疫功能的影响[J].齐齐哈尔医学院学报,2003,24(3):243-244.
[68]曹永孝,郑建普,陶小军,等.九节龙皂苷Ⅰ对坏磷酰胺模型小鼠免疫功能的影响[J].中国药学杂志.2005,40(20):1553-1571.
[69]刘长青兴,周岱翰,陈林香,等.参芪固本方对小鼠Lewis肺癌的抑制作用[J].广州中医药大学学报.2006,23(5):406-409.
[70]高绍荣,夏海平,张华,等.乳腺癌TAM疗后综合征/医药疗法六味地黄汤加味/治疗应用[J].国医论坛.2005,20(2):24-25.
[71]马岩,张锐,于小风,等.黄菇多糖对荷瘤小鼠化疗的减毒增效作用[J].中草药.2006,37(8):1199-1202.
[72]齐春会,付艳荣,张永祥,等.六味地黄多糖CA4-3对小鼠B细胞功能的作用[J].中国药理学通报.2001,17(4):469-473.
[73]柴可群,林胜友.中药对肿瘤免疫调节的实验研究进展[J].中国中医药信息杂志.2003.10(8):81-82.
[74]韩世愈.中药抗肿瘤免疫增效的研究进展[J].中国中医急症.2005,14(1):73-74.
[75]周洁,李竹庭.中药与肿瘤免疫.2004,21(3):227-228.
[76]肖颖,李覃.中医药抗肿瘤作用机制的研究进展[J].中国医学杂志.2008,6(3):38-40.
[77]Ishihara Y,Fujii T.The role of neutrophils as cytotoxic cells in lung metastasis:suppression of tumor cell metastasis by a biological response modifier(pSK)[J].In Vivo.1998,22(2):175-182.
[78]Moragoda L,Jaszewski R,Majumd A p.curcumin induced modelation of cell cycle and apoptosis in gastric and colon cancer cells[J].Anticancer Research.2001,21(2):873.
[79]Chaudhuri T.pal S,Agwarwal M I,et al.Curcumin induce sapeptosis in human breast cells through p53-dependent Bax induction[J].FEBS Letters.2002,512(1-3):334-340.
[80]江敏.姜黄素对体外人脐静脉血管内皮细胞增殖及凋亡作用的实验研究[J].福建中医学院学报.2007,17(3):53-55.
[81]刘东颖,谢广茹,史玉荣,等.冬虫夏草对乳腺痛细胞凋亡的诱导及相关基因表达的调控[J].天津医科大学学报.2007,13(2):206-209.
[82]邓尉英,范晓瓤,杨如红,等.参杞合剂对人鼻咽癌细胞CNE细胞周期及凋亡的影响[J].中国微生态学杂志.2007,19(3):246-248.
[83]Li Dan-Rong,ZHANG Wei,TANG Dong-ping,et al.Inhibitory efects of lea polyphenols on telomerase and its ability to induce apoptosis of BEI-7404 human hepatocellular carcinoma cell[J].Chinese Pharmaeolf Glcal Builetin.2003,19(8):934-939.
[84]郑国灿,李智英.丹参酮Ⅰ对HepG2细胞抑制作用的体外实验研究[J].现代医学.2004,32(5):296-298.
[85]李海霞,唐峰,王文娟,等.耐药逆转剂对人乳腺癌细胞p-糖蛋白、EMMpRIN和MMp表达的影响[J].复旦学报:医学版.2008,35(4):498-503.
[86]李贵海,王枚,孙付军,等.苦参碱逆转小鼠S180肿瘤细胞获得性多药耐药基因关表达产物过发表达的研究[J].中药材.2006,29(1):40-42.
[87]李贵海,孙付军,王宁,等.苦参碱干预获得性多药耐药小鼠S180肿瘤细胞相关生物因子p170过度表达与细胞凋亡的相关性[J].中药材.2005,28(4):310-312.
[88]黄煜伦,周幽心,周岱,等.雷公藤红素抑制血管生成的实验研究[J].中华肿瘤杂志.2003,25(5):429-432.
[89]楚延春.前列腺癌的病因病机初探[J].河南医药学刊.1997,12(4):14-16.
[90]马国花,吴燕敏,魏睦新.魏睦新采用中医待机疗法治疗早期前列腺癌经验[J].中国中医药信息杂志.2008,15(9):88-89.
[91]丁永锋,张亚大,朱子军,等.77例前列腺癌中医证型特点与临床相关因素分析[J].中国中西医结合外科杂志.2006,12(6):528-530.
[92]赵映前.试论前列腺癌的中医学研究思路与方法[J].中医药研究.2000,16(3):2-6.
[93]李恒山,杨玉霞.中医药治疗晚期前列腺癌12例报告[J].四川中医.2004,22(5):48.
[94]卢伟.王居祥主任医师治疗前列腺癌经验举隅[J].南京中医药大学学报.2005,21(3):186-187.
[95]宋竖旗,李灿.张亚强对晚期前列腺癌病因病机的认识[J].中国中医基础医学杂志.2008,14(2):131,133.
[96]张剑.李辅仁治疗前列腺癌睾丸摘除术后诸症的经验[J].中医杂志.1998,39(2):83.
[97]李日庆.实用中西医结合泌尿男科学,北京:人民卫生出版社.1995,1:186-190.
[98]郑伟达.前列腺疾病中医诊疗学,北京:北京科学技术出版社.140-153.
[99]邵梦扬,王守章.中西医结合临床肿瘤内科学,天津:天津科技翻译出版社.321-329.
[100]王涛.前列腺癌的中医药治疗[J].光明中医.2004,19(2):31-33.
[101]曹志成.中西医理论探讨前列腺癌[J].中华现代中西医杂志.2005,3(15):1361-1366
[102]彭煜,彭培初.泉安方治疗晚期前列腺癌骨转移痛初探:附18例报告[J].中国男科学杂志.2004,18(4):46-48.
[103]厉将斌,王沛,那彦群,等.前列腺癌中医药治疗的经验与思路[J].中国中西医结合杂志.2002,22(6):425-425.
[104]侯成饮,陈素嫣.扶正除湿饮治疗晚期前列腺癌5例疗效观察[J].山东中医杂志.1996,15(增刊):28.
[105]贾红巧,吴世华,吴骏.中药灵芝孢子油治疗前列腺癌的临床分析[J].男科医学.2005,(4):18-19.
[106]南勋义,贺大林,党建功,等.鸦胆子油乳治疗中晚期前列腺癌疗效观察[J].临床泌尿外科杂志.1998,13(12):531-533.
[107]南勋义,贺大林,王明珠,等.前列腺癌经去势术加中药治疗后pSA和性激素变化的意义[J].临床泌尿外科杂志.2004,19(12):715-717.
[108]董树猛.中西医结合治疗前列腺癌30例临床疗效分析[J].中华临床医学研究杂志.2007.13(4):533.
[109]李承功.周智恒治疗前列腺疾病经验[J].江西中医药.2002,33(2).5-5
[110]张亚强,林飞.前列消癥汤治疗前列腺癌的临床观察[J].中国中西医结合外科杂志.2006,12(2):83.
[111]钟亮,赖海标,黄智峰,等.中西医结合治疗晚期前列腺癌疗效观察[J].现代中西医结合杂志.2005,14(4).480-480,560.
[112]黄智峰,赖海标,曾晔,等.肿节风疰射液对中晚期前列腺癌26例pSA、FpSA的影响[J].中医研究.2006,19(11):25.
[113]陈铭,高松占,蔡甄波.消瘀散结灌肠剂治疗晚期前列腺癌18例[J].甘肃中医.2007,20(7):42-43.
[114]Hammar M,Frisk J,Grimas,et al.Acupuncture treatment of vaso-motor symptoms in men with prostatic carcinomaia pilot study[J].J Urol.1999,161(3):853.
[115]徐建国.前列腺癌汤配合针刺治愈前列腺癌验案[J].吉林中医药.2004,24(9):55
[116]顾正勤,孙颖浩.植物制剂抗前列腺癌研究进展[J].J ClinUrol.2003,18(5):3009.
[117]Hsieh T,ChenSS,WangX,etal.Regulation of androgen receptor(AR)and prostate specific antigen(PSA) expressioninthean drogen-respomive human prostate LNCap cells by ethanocextracts of the Chinese herbal preparation PC-SPEA[J].BiochemM ol Biol Int.1997,42:535-544.
[118]陈伟,李澄棣.治疗前列腺癌的中草药PC-SPES[J].中华泌尿外科杂志.2002,23(6):378-379.
[119]张群豪,陈可冀.美国PC-SPES(中药复方)抗前列腺癌的研究进展[J].中国中西医结合杂志,2001,21(4):295-299.
[120]Dela Taille A,Buttyan Hayeko,et al.Herbaltherapy PC-SPES:in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer[J].J Urol.2000,164(4):1229-1234.
[121]SmallEJ,FrohlichM Bok et al.prospectiveof the herbal supplement PC-SPES in patients with progressive prostate cancer[J].J Clin Oncol,2000,18(21):3595-3603.
[122]张亚强,林飞.前列消癥汤对前列腺癌C57小鼠移植瘤的抑制作用[J].中国中西医结合外科杂志,2005,11(6):505.
[123]张辉,吕家驹,丁森泰,等.吴茱萸碱诱导前列腺癌PC-3细胞凋亡机制的实验研究[J].中国老年医学杂志,2007,27(7):1230.
[124]张蜀武,张培海,常德贵.人参胡核汤对人前列腺癌PC-3细胞增殖的抑制作用[J].中国男科学杂志,2007,21(6):7.
[125]丁家欣,张立石,张玲,等.虎耳草提取物对前列腺癌细胞凋亡的影响[J].中国中医基础医学杂志.2005,11(12):905,907.
[126]王军,赵映前.化癥胶囊方剂诱导前列腺癌细胞系PC-3凋亡的实验研究[J].湖北中医学院学报.2004,6(2):18-19.
[127]Chan FL,Choi HL,Chen ZY,et al.Induction of apoptosis inprostate cancer cell lines by a flavonoid baiclin[J].J Cancer Letters.2000,160(2):219-228.
[128]师长进,俞莉章.番茄红素抗前列腺癌的作用研究现状[J].现代泌尿外科杂志.2002,7(4):245-246.
[129]Gionannucci EA,Rimm EB,et al.lntake of carotenoids andretinal in relationship to risk of prostate cancer[J].J Natl Cancer Inst.1995,87:1767-1776.
[130]唐莉莉,曾祥斌.番茄红素对人前列腺癌细胞生长的影响[J].中国公共卫生.2001,17:118-119.
[131]刘雪莉,张亮,钱伯初,等.枸杞子抑制人前列腺细胞增殖活性成分的研究[J].浙江省医学科学院学报.2000,11(2):1.
[132]师长进,俞莉章,那彦群,等.中药紫龙金对转移性前列腺癌体外增殖及侵袭能力的影响[J].中华外科杂志.2003,41(6):473-473.
[133]吕立国,古炽明,王昭辉,等.陈志强教授对晚期前列腺癌中医病因病机的探讨 [J].新中医.2007,39(2):81-82.
[134]吕立国,代睿欣,王昭辉,等.陈志强教授扶正抑瘤法治疗晚期前列腺癌临床经验介绍[J].新中医.2007,39(5):91.
[135]古炽明,吕立国,王昭辉,等.中西医结合治疗前列腺癌的临床观察[J].广东药学院学报.2007,23(1):92-93.
[136]吕立国,陈志强,王树声,等.中西医结合扶正抑瘤法治疗前列腺癌142例临床观察[J].新中医.2008,40(1):26-27.
[137]郝素珍,王桂琴.实用医学免疫学[M].北京:高等教育出版社,2005,2:31-32.
[138]Ikeda H,Chamoto K,TSuji T,et al.The critical role of type Ⅰ innate and acquired immunity in tumor immunotherapy[J].Cancer Sci.2004.95:697-703.
[139]Wu Y,Wan T,Zhou x,et al.Hsp70-like protein l fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL respon- se by dendritic cell vaccine[J].Cancer Res.2005.65:4947-4954.
[140]Hatam L,Sehuval S,Bonagura VR.Flow cytometric analysis of natural killer cell function as a clinical assay[J].Cytometry.1994,16:59,68.
[141]Meades R.Bromelow KV,Westby M,et al.Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells an d CD3+CD56+ NK-T celIs in whole blood[J].Cytometry.2000,39:72-78.
[142]韩晓红,石远凯,冯奉仪,等.流式细胞仪分析肿瘤患者免疫功能变化[J].实用癌症杂志.1999,14(5):273-275.
[143]王书奎,周振英,吴晓柳,等.恶性肿瘤转移与患者免疫活性细胞水平的相关性研究[J].中国免疫学杂志.2003,19(11):786-788.
[144]陈晓琳,戴勇,李富荣,等.恶性肿瘤患者T细胞及NK细胞功能研究及临床意义[J].中国现代医学杂志.2002,12(2):41-43.
[145]徐从高,张茂宏,畅兴季,等.癌-肿瘤学原理和实践[M].济南:山东科学技术出版社.2000,5:49-70.
[146]陈灏珠.实用内科学[M].北京:人民卫生出版社.2002,11:94.
[147]何球藻,吴厚生,曹雪涛.细胞与分子免疫学[M].上海:上海科学技术文献出版社.1997.146.
[148]殷缨,张盈华,张利朝,等.恶性肿瘤患者T细胞亚群与红细胞免疫功能的变化及其相关性分析[J].实用癌症杂志.2001.16(2):171-173.
[149]Soygur T,Beduk Y,Yaman O,et al Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma[J].Urology.1999,53(1):88-91.
[150]Bentdal OH,Froland SS,Bosnes V,et al.Alteration of lymphocyte subsets in blood may predict resectibility in carcinoma of cardia or oesophogus[J].Cancer Letters.1996,100:133-138.
[151]Liua Y,poona RT.Hughesb J,et al.Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma[J].Clin Immunol.2005.114:174,182.
[152]曹健,乔颖,陈大伟.胃肠道恶性肿瘤患者NK细胞和T细胞亚群的改变[J]中华肿瘤杂志.1997.19(2):133-136.
[153]金从国,王熙才,伍治平,等.癌症患者外周血T细胞亚群水平及临床意义[J]肿瘤研究与临床.2003,15(1):33-36.
[154]Cho Y,M iyamoto M,Kato K,et al.CD4+ and CI)8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma[J].Cancer Res.2003,63(7):1555-1559.
[155]鞠秀丽,孙念政,刘继玲,等.儿童急性淋巴细胞白血病患者T淋巴细胞免疫功能的研究.临床血液学杂志.2004,17(2):84-86.
[156]Skinnider BF,Mak TW.The role of cytokines in classical Hodgkin lymphoma [J].Blood.2002,99(12):4283-4297.
[157]Farag S S,VanDeusen J B,Fehniger T A et al.Biology and clinical impact of human natural killer cells[J].Int J Hematol.2003,78(1):7-17.
[158]Kuhista B,Trieh K,Blahovee H et al.Hyperthermia increases the susceptibility of chondro anti teosareoma cells to natural killer cell mediated lysis[J]Anticancer Res.2002,22(2A):789-792.
[159]Seki S,Habu Y,Kawamura T,et al.The liver as a crucial organ in the first line host defense:the roles of Kupffer cells,NK cell and NK1,1Ag+T cell in T helper 1 immune responses[J].Immunological Rev.2000,174:35-46.
[160]Mark JS.Kevin YRT.Shayna EAS,et al.Defferential tumor surveillance by NK and NKT cells[J].J Exp Med,2000,101:661,668.
[161]周启明,吴沛宏.T淋巴细胞亚群及NK细胞变化与原发性肝癌预后的关系[J].介入放射学杂志.2005,14(6):635-637.
[162]胡挺,张顺,徐焕龙.鼻咽癌患者外周血T淋巴细胞亚群和NK细胞检测.中国肿瘤.2006,15(3):195-196.
[163]邢爱民,孙玉凤,陈玉凤.肺癌患者外周血T淋巴细胞亚群变化及其临床意义[J].肿瘤学杂志.2004,10(3):173-174.
[164]陈文宽,宋明,陈福进,等.喉咽鳞癌患者外周血T淋巴细胞亚群和NK细胞活性分析[J].癌症.2006,25(10):1300-1302.
[165]Kuss I,Hathaway B,Ferris R L,et al.Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease[J].Adv Otorhinolaryngol.2005,7(62):161-172.
[166]赵代伟,叶晖,王南鹏,等.甲状腺癌患者外周血T细胞亚群和NK细胞活性动态变化及临床意义[J].山东医药.2008,48(26):78-79.
[167]李惠萍,李世荣.卵巢恶性肿瘤患者外周血T淋巴细胞亚群NK细胞活性检测的临床意义[J].中华临床新医学.2002,2(1):13-14.
[168]秦晓云,薛际航.脑肿瘤患者外围血T淋巴细胞亚群测定分析.中国误诊学杂志.2008,8(30):7349-7350.
[169]梁索源,李巧霞,张超,等.食管癌患者红细胞免疫功能和T细胞亚群、自然杀伤细胞活性的研究[J].临床荟萃.2008,23(16):1184-1185.
[170]宁军,龚浩.中晚期肿瘤患者T淋巴细胞和NK细胞检测的临床意义[J].实用全科医学,2007,5(7):587-588.
[171]邬露丹,徐炜峰,熊逸群.恶性肿瘤患者淋巴细胞亚群的测定及与癌胚抗原的关系[J].实验与检验医学.2008,26(1):57-58.
[172]何立丽,孙桂芝.孙桂芝治疗恶性肿瘤经验撷微[J].北京中医药.2008,27(12):932-933.
[173]贾文娟,邢秀玲,贾英杰,等.扶正合剂改善乳腺癌患者化疗副作用的临床观察[J].河北中医.2008,30(11):1141-1142,1148.
[174]汤桂梅,赵彦南,陈坤.芪甲扶正胶囊辅助化疗治疗中晚期非小细胞肺癌的临床观察[J].河北中医.2008,30(10):1025-1026.
[175]韩旭.扶正固本治疗癌症放化疗后白细胞减少症36例[J].四川中医.2007,25(10):69-70.
[176]熊墨年.略谈运用扶正抑癌治疗肿瘤的几点体会.实用中西医结合临床.2008,8(5):45-46.
[177]刘嘉湘.恶性肿瘤的中医药治疗—阴阳平衡与扶正治癌理论在癌症治疗中的应用[J].江苏中医药.2008,40(9):1-2.
[178]曾英.肿瘤从虚论治.吉林中医药.2008,28(1):3-4.
[179]华海清.扶正培本药物治疗恶性肿瘤的现代研究[J].中国中药杂志.2008,33(9):1094-1097.
[180]李万辉.中医扶正疗法在恶性肿瘤姑息治疗中的地位[J].北京中医药.2008,27(2):112-114.
[181]杜娟.中药抗肿瘤免疫的研究进展[J].中医药临床杂志.2004,16(5):507-509.
[182]Arlen PM,Gulley JL,Todd N,et al.Anti-androgen,vaccine and combination therapy in patients with nonmetastratic hormone refractory prostate cancer[J]. J Urol.2005,174(2):539-546.
[183]王宇岭,高远,殷红,等.参芪扶正注射液对恶性胃肠道肿瘤患者免疫功能的影响[J].中药新药与临床药理.2008,19(6):506-507.
[184]朱琨,李康,党诚学.参芪扶正注射液对乳腺癌术后行CEF方案化疗患者免疫功能的影响[J].现代肿瘤医学.2008,16(10):1712-1714.
[185]林梅英,关莹,侯恩存.黄芪注射液对化疗副作用的拮抗作用的临床观察[J].广州中医药大学学报.2006,23(2):127-129.
[186]罗晶,郭焱.人参养荣汤对小鼠免疫功能的调节[J].中国现代医学杂志.2002,12(5):27-28.
[187]马红,沈继泽.金匮肾气丸免疫调节作用的实验研究[J].中药药理与临床.2000,16(6):5-6.
[188]梁超,张胜华,蔡照弟,等.早期肠内应用四君子汤对消化道肿瘤术后患者免疫功能的影响[J].中国中西医结合杂志.2005,25(12):1070-1073.
[189]白广德,练祖平,黄丁平,等.八珍汤加味配合西医治疗对中晚期肝癌患者生存质量及免疫功能的影响[J].四川中医.2008,26(4):73-75.
[190]曹志然,韩艳梅,戎瑞雪,等.十全大补汤对移植乳腺癌小鼠免疫抑瘤作用的实验研究[J].时珍国医国药.2007,18(4):F0003-F0004.
[191]徐勇,卢杏生.生脉注射液对胃癌术后免疫功能的影响[J].辽宁中医杂志.2008,35(10):1451-1453.
[2]刘耀庭,李秀霞,程伟,等.泌尿外科肿瘤发病情况的变化[J].临床泌尿外科杂志.1997,12(1):47-50.
[3]Grossfeld GD,Stier DM,Flanders SC,et al.Use of second treatment following definitive local therapy for prostate cancer:data from the caPSURE database[J].J Urokl.1998,160:1398-1404.
[4]Luyao GL,Potosky AL,Albertsen PC,et al.Follow-up prostate cancer treatments after radicalprostatectomy:a population-based study[J].J Natl Cancer Inst.1996.88:166-173.
[5]BoTr S R J.Management of recurrent disease after radical prostatectomy[J].Prostate Cancer Prostatic Dis.2004,7:211-216.
16]Wingo pA,Cardinez CJ,Landis SH,et al.Long-term trends in cancer mortality in the United States,1930-1998[J].Cancer.2003,97(12 Suppl):3133-3275.
[7]Ceraline J,Cruchant MD,Erdmann E,et al.Constitutive activation of the androgen receptor by a point mutation in the hinge region:a new mechanism for androgen-independent growth in prostate cancer[J].Int J Cancer.2004,108:152-157.
[8]Bubendof L,Kononen J,Koivisto p,et al.Survey of gene amplification during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays[J].Cancer Res.1999,59:803-806.
[9]Edwards J,Krishna N S,Grigor K M,et al Androgen receptor gene amplication and protein expression in hormone refractory prostate cancer[J].Br J cancer.2003,89:552-526.
[10]Kang H Y,Yeh S,Fujimoto N,et al.Cloning and characterization of human prostate coactivator ARA54,a novel protein that associates with the androgen receptor[J].J Biol Chem.1999,274:8570-8576.
[11]Miyamoto H,Yeh S,Wilding G,et al.promotion of agonist activity of antiandrogens by the of androgen receptor coactivator,ARA70.in human prostate cancer DU145 cells[J].Proc Nail Acad Sci USA.1998,95:7379-384.
[12]Yeh S,Lin HK,Kang HY,etal.From HER2/Neu signal cascade to androgen receptor an dits coactivator:a novel pathway by induction of androgen target genes through MAp kinase in prostate cancer cells[J].Proc Nail Acad Sci USA.1999,96:5458-5463.
[13]Gao X,Loggie B W,Nawaz Z.The roles of sex steroid receptor coregulators in cancer[J].Mol Cancer.2004,14:1-7.
[14]Smith C L,O Malley B W.Coregulator function:a key to understanding tissue specificity of selective receptor modulators[J].Endo Rev.2004,25:45-71.
[15]Sadar MD.Androgen-independent induction of prostate specifican tigen gene expression via cross-talk between the androgenreceptor and protein kinase A signal transduction pathways[J].J Biol Chem.1999,274:7777-7783.
[16]Yang L,Wang L,Lin HK,et al.Interleukin-6 diferentially regulat-es androgen receptor tansactivation via pI3K-Akt,STAT3 and MApK,three distinct signal pathways in prostate cancer cells[J].Biochem Biophys Res Commun.2003,305:462-469.
[17]Culig Z,Hohisch A,Cronauer M V,et al.Regulation of prostatic growth and function by peptide growth factors[J].Prostate.1996,28:392-405.
[18]Tan J,Sharief Y,Hamil K G,et al.Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCap cells[J].Mol Endocrinol.1997,11(4):450-459.
[19]王建功,闫天中.皮质醇与雄激素非依赖前列腺癌的关系[J].实用医药杂志.2004,21:595-596.
[20]Cofey RN,Watson RW,O Neill AJ,et al.Androgen-mediatedresistance to apoptosis[J].prostate,2002.53:300-309.
[21]Lip.Nicosia SV.Bai W.Antagonism between pTEN/MMAC1/TEp-1 and androgen receptor in growth and apoptosis of prostatic cancer cells[J].J Biol Chem,2001,276:20444-20450.
[22]Jaggi M,Rao pS,Smith DJ,et al.protein kinase Cμ is down-regulated in androgen-independent prostate cancer[J].Biochem Biophys Res Commun.2003,307:254-260.
[23]Halkidou K,Gaughan L,Cook S,etal.Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer[J].Prostate,2004,59:177-189.
[24]park J J,Irvine R A,Buchanan G,et al.Breast cancer susceptibility gene 1(BRCA1) is a coactivator of the androgen receptor[J].Cancer Res.2000,60:5946.
[25]Ryan CJ,Small EJ.Role of secondary hormonal therapy in the management of recurrent disease[J].Urology.2003,62(Suppl 6B):87-94.
[26]孙忠全 钱伟庆 宋建达.比卡鲁胺治疗雄激素非依赖性前列腺癌.中国癌症杂志[J].2006,16(2):158-159.
[27]Kelly WK,Scher HI.prostate specific antigen decline after antiandrogen withdrawal syndrome[J].J Urol.1993,149:607-609.
[28]华立新 吴宏飞 眭元庚,等.比卡鲁胺治疗激素抵抗性前列腺癌[J].中华泌尿外科杂志.2005,26(6).383-385.
[29]Kucuk O,Fisher E,Moinpour CM,et al.phase Ⅱ trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy hormonal therapy failed:a Southwest Oncology Group Study(SWOG92 35)[J].Urol.2001,58(1):53-58.
[30]OH WK,Kantoff pW.Management of hormone refractory prostate cancer:current standards and future prospects[J].J Uroi.1998,160(4):1220-1229.
[31]Miyake H,Hara I,Eto H.Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone refractory prostate cancer[J].BJU Int.2005,96(6):791-795.
[32]Graft JR.Emerging targets in the AKT pathway for treatment of androgen independent prostatic adenocarcinoma[J].Expert Opin rher Targets.2002,6(1):103-113.
[33]Yang F,Fuxhorn Jh,Ressler SJ.Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis[J].Cancer Res.2005,65(19):8887-8895.
[34]paramita M Ghosh,Shazli N Malik,Roble G Bedolla,et al.Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocrine Related[J].Cancer,2005,12:119-134.
[35]Smith DC,Redman BG,Flaherty LE,et al.A phase I1 trial of oral diethyl stilbesterol asasecond line hormonal agent in advanced prostate cancer[J].Urology.1998.52:257-260.
[36]Siddiqui K,Abbas F,Biyabani SR,et al.Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer[J].J pak Med Assoc,2004.54:445-447.
[37]孙忠全,钱伟庆,宋建达.己烯雌酚治疗雄激素非依赖性前列腺癌12例疗效分析[J].中华外科杂.2006,44(18).1265-1266.
[38]曹野,王进,聂勇,等.经泵动脉灌注抗癌药治疗雄激素非依赖性前列腺癌的疗效评价.介入放射学杂志.2008,17(9).641-644.
[39]Ronald DW,Mario AE,Ian T,et al.A multicenter comparionof docetaxel given weekly or every three weeks prednisone with mitoxantrone prednisone in patients with hormone-refractory prostate cancer:Study TAX-327[J].ASCO Abs,2004.
[40]Serafini AN,Houstion SJ,Resche I et al:palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam:a double blind placebo controlled clinical trial[J].J Clin Oncol.1998,16:1574-1581.
[41]Mikata K,Uemura H,Ohuchi H,et al.Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene:gene transfer by electroporation [J].Mol Cancer Ther.2002,1(4):247-252.
[42]Huang S.Houghton pJ.Targeting m1UR signaling for cancer therapy[J].Curt Opin Pharmacol.2003,3:371-377.
[43]Sandra L,Krueckl,Robert A,et al.Increased Insulin-Like Growth Factor Ⅰ Receptor Expression and Signaling Are Components of Androgen- Independent progression in a Lineage-Derived prostate Cancer progression Model[J].Cancer Research.2004,64:8620-8629.
[44]padley RJ,Dixon DB,Wu Wong JR.Effect of castration on endothelin receptors[J].Clin Sci(Lond).2002,103(Suppl 48):442S-445S.
[45]高江平,洪宝发.雄激素非依赖性前列腺癌的治疗策略[J].中华泌尿外科杂志.2005,26(4):286-287.
[46]Emil A.Tanagho,Jack W.McAninch.Smiths General Urology 16e[M].Mc Graw-Hill Companies,Inc.2004.
[47]Hahne M,Rimoldi D,Schroter M,et al.Melanoma cell expression of Fas(Apo-1/CD95) ligand:implications for tumor immune escape[J].Science.1996,274(5291):1363.
[48]pandha,Hardev S,Menard S,et al.dendritic cell immunotherapy for urological cancers using cryopreserved allogenein tumor lysate-pulsed cell[J].BJU International.2004,94(3):412.
[49]Uyl-de Groot CA,Vermorken JB,Hanna MG Jr,et al.Immunotherapy with autologous tumor cell BCG vaccine in patients with colon cancer:a prospective study of medical and economic benefits[J].Vaccine.2005,23(17-18):2379-2387.
[50]Jocham D,Richter A,Hoffmann L,et al.Auvant autologous renal tumo- ur cell vaccine and risk of tumour progression in patients with renal cell carcinoma after radical nephrectomy:phase Ⅲ,randomised controlled trial[J].Lancet.2004,363(9409):594-599.
[51]Nemunaitis J,Nemunaitis J.A review of vaccine clinical trials for- nonsmall cell lung cancer[J].Expert Opin Biol Ther.2007,7(1):89-102.
[52]孙丽斌,张积仁,胡喜钢.异种抗原免疫序贯瘤内注射对肿瘤浸润淋巴细胞的影响[J].广东医学.2009,30(1):54-56.
[53]齐士勇,王萌,徐勇.前列腺癌组织中树突状细胞的变化及以此为基础的免疫治疗[J].中华男科学杂志.2007.5(13):453-456.
[54]丘少鹏,陈辉熔,邓春华,等.前列腺癌肿瘤微环境树突状细胞与T细胞免疫的关系[J].中山医科大学学报.2002,23(2 J:127-128,131.
[55]Mu LJ,Kyte JA,Kvalheim G,et al.Immunotherapy with allotumour mRNA.transfected dendritic cells in androgen-resistant prostate cancer patients[J].Br J Cancer.2005,93(7):749-56.
[56]Su Z,Dannull J,Yang BK,et al.Telomerase mRNA transfected dendritic cells stimulate antigen:specific CD8 and CD4 T cell responses in patients with metastatic prostate cancer[J].J Immunol.2005,174(6):3798-3807.
[57]Dreicer R.See W.A,Klein E.A.phase Ⅱ trial of GM-CSF in advanced prostate cancer[J].Invest.New Drugs.2001,19:261-265.
[58]Rini BI.Weinberg V,Bok R,el al.prostate-specific antigen kinetic as a measure of granulocyte macrophage colony stimulating factor with progression of prostate cancer[J].J Clin Oncol.2003,21:99-I05.
[59]Trudel S,Trachtenberg J,Toi A,et al.A phase Ⅰ trial adenovector-mediated delivery of interleukin-2(AdIL-2) in high-risk localized prostate cancer[J].Cancer Gene Ther.2003,10(10):755-763.
[60]Simons JW,Sacks N.Granulocyte-macrophage colony-stimularing factor transduced allogeneie cancer cellular immunotherapy:the GVAX vaccine for prostate cancer[J].Urol Oncol.2006,24(5):419-424.
[61]郁仁存.中医药防治肿瘤的作用和展望[J].中国中西医结合杂志.2007,27(5):389-390.
[62]何光星,刘洁,王笳,等.中医药抗肿瘤作用机理研究现状[J].2008.26(8):47-50.
[63]胡艳,曹洋,易华,等.仙鱼汤对Lewis肺癌荷瘤小鼠免疫功能的影响[J].广州中医药大学学报.2008,25(6)522-524,527.
[64]沈旭华,陈长勋.新云芝糖肽对S180荷瘤小鼠环磷酰胺化疗的增效减毒作用[J].肿瘤.2008,28(7):572-576.
[65]侯冰宗,舒晓春,周少朋,等.中药艾迪注射液对大肠癌术后机体免疫功能的影响[J].第四军医大学学报.2008,29(10):933-935.
[66]万华,吴雪卿,董佳容,等.“乳癌术后方”抗高转移小鼠乳腺癌作用机制的研 究[J].肿瘤.2007,27(9).691-693,709.
[67]王琪,程德春,王磊.川芎嚎对荷瘤鼠化疗后免疫功能的影响[J].齐齐哈尔医学院学报,2003,24(3):243-244.
[68]曹永孝,郑建普,陶小军,等.九节龙皂苷Ⅰ对坏磷酰胺模型小鼠免疫功能的影响[J].中国药学杂志.2005,40(20):1553-1571.
[69]刘长青兴,周岱翰,陈林香,等.参芪固本方对小鼠Lewis肺癌的抑制作用[J].广州中医药大学学报.2006,23(5):406-409.
[70]高绍荣,夏海平,张华,等.乳腺癌TAM疗后综合征/医药疗法六味地黄汤加味/治疗应用[J].国医论坛.2005,20(2):24-25.
[71]马岩,张锐,于小风,等.黄菇多糖对荷瘤小鼠化疗的减毒增效作用[J].中草药.2006,37(8):1199-1202.
[72]齐春会,付艳荣,张永祥,等.六味地黄多糖CA4-3对小鼠B细胞功能的作用[J].中国药理学通报.2001,17(4):469-473.
[73]柴可群,林胜友.中药对肿瘤免疫调节的实验研究进展[J].中国中医药信息杂志.2003.10(8):81-82.
[74]韩世愈.中药抗肿瘤免疫增效的研究进展[J].中国中医急症.2005,14(1):73-74.
[75]周洁,李竹庭.中药与肿瘤免疫.2004,21(3):227-228.
[76]肖颖,李覃.中医药抗肿瘤作用机制的研究进展[J].中国医学杂志.2008,6(3):38-40.
[77]Ishihara Y,Fujii T.The role of neutrophils as cytotoxic cells in lung metastasis:suppression of tumor cell metastasis by a biological response modifier(pSK)[J].In Vivo.1998,22(2):175-182.
[78]Moragoda L,Jaszewski R,Majumd A p.curcumin induced modelation of cell cycle and apoptosis in gastric and colon cancer cells[J].Anticancer Research.2001,21(2):873.
[79]Chaudhuri T.pal S,Agwarwal M I,et al.Curcumin induce sapeptosis in human breast cells through p53-dependent Bax induction[J].FEBS Letters.2002,512(1-3):334-340.
[80]江敏.姜黄素对体外人脐静脉血管内皮细胞增殖及凋亡作用的实验研究[J].福建中医学院学报.2007,17(3):53-55.
[81]刘东颖,谢广茹,史玉荣,等.冬虫夏草对乳腺痛细胞凋亡的诱导及相关基因表达的调控[J].天津医科大学学报.2007,13(2):206-209.
[82]邓尉英,范晓瓤,杨如红,等.参杞合剂对人鼻咽癌细胞CNE细胞周期及凋亡的影响[J].中国微生态学杂志.2007,19(3):246-248.
[83]Li Dan-Rong,ZHANG Wei,TANG Dong-ping,et al.Inhibitory efects of lea polyphenols on telomerase and its ability to induce apoptosis of BEI-7404 human hepatocellular carcinoma cell[J].Chinese Pharmaeolf Glcal Builetin.2003,19(8):934-939.
[84]郑国灿,李智英.丹参酮Ⅰ对HepG2细胞抑制作用的体外实验研究[J].现代医学.2004,32(5):296-298.
[85]李海霞,唐峰,王文娟,等.耐药逆转剂对人乳腺癌细胞p-糖蛋白、EMMpRIN和MMp表达的影响[J].复旦学报:医学版.2008,35(4):498-503.
[86]李贵海,王枚,孙付军,等.苦参碱逆转小鼠S180肿瘤细胞获得性多药耐药基因关表达产物过发表达的研究[J].中药材.2006,29(1):40-42.
[87]李贵海,孙付军,王宁,等.苦参碱干预获得性多药耐药小鼠S180肿瘤细胞相关生物因子p170过度表达与细胞凋亡的相关性[J].中药材.2005,28(4):310-312.
[88]黄煜伦,周幽心,周岱,等.雷公藤红素抑制血管生成的实验研究[J].中华肿瘤杂志.2003,25(5):429-432.
[89]楚延春.前列腺癌的病因病机初探[J].河南医药学刊.1997,12(4):14-16.
[90]马国花,吴燕敏,魏睦新.魏睦新采用中医待机疗法治疗早期前列腺癌经验[J].中国中医药信息杂志.2008,15(9):88-89.
[91]丁永锋,张亚大,朱子军,等.77例前列腺癌中医证型特点与临床相关因素分析[J].中国中西医结合外科杂志.2006,12(6):528-530.
[92]赵映前.试论前列腺癌的中医学研究思路与方法[J].中医药研究.2000,16(3):2-6.
[93]李恒山,杨玉霞.中医药治疗晚期前列腺癌12例报告[J].四川中医.2004,22(5):48.
[94]卢伟.王居祥主任医师治疗前列腺癌经验举隅[J].南京中医药大学学报.2005,21(3):186-187.
[95]宋竖旗,李灿.张亚强对晚期前列腺癌病因病机的认识[J].中国中医基础医学杂志.2008,14(2):131,133.
[96]张剑.李辅仁治疗前列腺癌睾丸摘除术后诸症的经验[J].中医杂志.1998,39(2):83.
[97]李日庆.实用中西医结合泌尿男科学,北京:人民卫生出版社.1995,1:186-190.
[98]郑伟达.前列腺疾病中医诊疗学,北京:北京科学技术出版社.140-153.
[99]邵梦扬,王守章.中西医结合临床肿瘤内科学,天津:天津科技翻译出版社.321-329.
[100]王涛.前列腺癌的中医药治疗[J].光明中医.2004,19(2):31-33.
[101]曹志成.中西医理论探讨前列腺癌[J].中华现代中西医杂志.2005,3(15):1361-1366
[102]彭煜,彭培初.泉安方治疗晚期前列腺癌骨转移痛初探:附18例报告[J].中国男科学杂志.2004,18(4):46-48.
[103]厉将斌,王沛,那彦群,等.前列腺癌中医药治疗的经验与思路[J].中国中西医结合杂志.2002,22(6):425-425.
[104]侯成饮,陈素嫣.扶正除湿饮治疗晚期前列腺癌5例疗效观察[J].山东中医杂志.1996,15(增刊):28.
[105]贾红巧,吴世华,吴骏.中药灵芝孢子油治疗前列腺癌的临床分析[J].男科医学.2005,(4):18-19.
[106]南勋义,贺大林,党建功,等.鸦胆子油乳治疗中晚期前列腺癌疗效观察[J].临床泌尿外科杂志.1998,13(12):531-533.
[107]南勋义,贺大林,王明珠,等.前列腺癌经去势术加中药治疗后pSA和性激素变化的意义[J].临床泌尿外科杂志.2004,19(12):715-717.
[108]董树猛.中西医结合治疗前列腺癌30例临床疗效分析[J].中华临床医学研究杂志.2007.13(4):533.
[109]李承功.周智恒治疗前列腺疾病经验[J].江西中医药.2002,33(2).5-5
[110]张亚强,林飞.前列消癥汤治疗前列腺癌的临床观察[J].中国中西医结合外科杂志.2006,12(2):83.
[111]钟亮,赖海标,黄智峰,等.中西医结合治疗晚期前列腺癌疗效观察[J].现代中西医结合杂志.2005,14(4).480-480,560.
[112]黄智峰,赖海标,曾晔,等.肿节风疰射液对中晚期前列腺癌26例pSA、FpSA的影响[J].中医研究.2006,19(11):25.
[113]陈铭,高松占,蔡甄波.消瘀散结灌肠剂治疗晚期前列腺癌18例[J].甘肃中医.2007,20(7):42-43.
[114]Hammar M,Frisk J,Grimas,et al.Acupuncture treatment of vaso-motor symptoms in men with prostatic carcinomaia pilot study[J].J Urol.1999,161(3):853.
[115]徐建国.前列腺癌汤配合针刺治愈前列腺癌验案[J].吉林中医药.2004,24(9):55
[116]顾正勤,孙颖浩.植物制剂抗前列腺癌研究进展[J].J ClinUrol.2003,18(5):3009.
[117]Hsieh T,ChenSS,WangX,etal.Regulation of androgen receptor(AR)and prostate specific antigen(PSA) expressioninthean drogen-respomive human prostate LNCap cells by ethanocextracts of the Chinese herbal preparation PC-SPEA[J].BiochemM ol Biol Int.1997,42:535-544.
[118]陈伟,李澄棣.治疗前列腺癌的中草药PC-SPES[J].中华泌尿外科杂志.2002,23(6):378-379.
[119]张群豪,陈可冀.美国PC-SPES(中药复方)抗前列腺癌的研究进展[J].中国中西医结合杂志,2001,21(4):295-299.
[120]Dela Taille A,Buttyan Hayeko,et al.Herbaltherapy PC-SPES:in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer[J].J Urol.2000,164(4):1229-1234.
[121]SmallEJ,FrohlichM Bok et al.prospectiveof the herbal supplement PC-SPES in patients with progressive prostate cancer[J].J Clin Oncol,2000,18(21):3595-3603.
[122]张亚强,林飞.前列消癥汤对前列腺癌C57小鼠移植瘤的抑制作用[J].中国中西医结合外科杂志,2005,11(6):505.
[123]张辉,吕家驹,丁森泰,等.吴茱萸碱诱导前列腺癌PC-3细胞凋亡机制的实验研究[J].中国老年医学杂志,2007,27(7):1230.
[124]张蜀武,张培海,常德贵.人参胡核汤对人前列腺癌PC-3细胞增殖的抑制作用[J].中国男科学杂志,2007,21(6):7.
[125]丁家欣,张立石,张玲,等.虎耳草提取物对前列腺癌细胞凋亡的影响[J].中国中医基础医学杂志.2005,11(12):905,907.
[126]王军,赵映前.化癥胶囊方剂诱导前列腺癌细胞系PC-3凋亡的实验研究[J].湖北中医学院学报.2004,6(2):18-19.
[127]Chan FL,Choi HL,Chen ZY,et al.Induction of apoptosis inprostate cancer cell lines by a flavonoid baiclin[J].J Cancer Letters.2000,160(2):219-228.
[128]师长进,俞莉章.番茄红素抗前列腺癌的作用研究现状[J].现代泌尿外科杂志.2002,7(4):245-246.
[129]Gionannucci EA,Rimm EB,et al.lntake of carotenoids andretinal in relationship to risk of prostate cancer[J].J Natl Cancer Inst.1995,87:1767-1776.
[130]唐莉莉,曾祥斌.番茄红素对人前列腺癌细胞生长的影响[J].中国公共卫生.2001,17:118-119.
[131]刘雪莉,张亮,钱伯初,等.枸杞子抑制人前列腺细胞增殖活性成分的研究[J].浙江省医学科学院学报.2000,11(2):1.
[132]师长进,俞莉章,那彦群,等.中药紫龙金对转移性前列腺癌体外增殖及侵袭能力的影响[J].中华外科杂志.2003,41(6):473-473.
[133]吕立国,古炽明,王昭辉,等.陈志强教授对晚期前列腺癌中医病因病机的探讨 [J].新中医.2007,39(2):81-82.
[134]吕立国,代睿欣,王昭辉,等.陈志强教授扶正抑瘤法治疗晚期前列腺癌临床经验介绍[J].新中医.2007,39(5):91.
[135]古炽明,吕立国,王昭辉,等.中西医结合治疗前列腺癌的临床观察[J].广东药学院学报.2007,23(1):92-93.
[136]吕立国,陈志强,王树声,等.中西医结合扶正抑瘤法治疗前列腺癌142例临床观察[J].新中医.2008,40(1):26-27.
[137]郝素珍,王桂琴.实用医学免疫学[M].北京:高等教育出版社,2005,2:31-32.
[138]Ikeda H,Chamoto K,TSuji T,et al.The critical role of type Ⅰ innate and acquired immunity in tumor immunotherapy[J].Cancer Sci.2004.95:697-703.
[139]Wu Y,Wan T,Zhou x,et al.Hsp70-like protein l fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL respon- se by dendritic cell vaccine[J].Cancer Res.2005.65:4947-4954.
[140]Hatam L,Sehuval S,Bonagura VR.Flow cytometric analysis of natural killer cell function as a clinical assay[J].Cytometry.1994,16:59,68.
[141]Meades R.Bromelow KV,Westby M,et al.Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells an d CD3+CD56+ NK-T celIs in whole blood[J].Cytometry.2000,39:72-78.
[142]韩晓红,石远凯,冯奉仪,等.流式细胞仪分析肿瘤患者免疫功能变化[J].实用癌症杂志.1999,14(5):273-275.
[143]王书奎,周振英,吴晓柳,等.恶性肿瘤转移与患者免疫活性细胞水平的相关性研究[J].中国免疫学杂志.2003,19(11):786-788.
[144]陈晓琳,戴勇,李富荣,等.恶性肿瘤患者T细胞及NK细胞功能研究及临床意义[J].中国现代医学杂志.2002,12(2):41-43.
[145]徐从高,张茂宏,畅兴季,等.癌-肿瘤学原理和实践[M].济南:山东科学技术出版社.2000,5:49-70.
[146]陈灏珠.实用内科学[M].北京:人民卫生出版社.2002,11:94.
[147]何球藻,吴厚生,曹雪涛.细胞与分子免疫学[M].上海:上海科学技术文献出版社.1997.146.
[148]殷缨,张盈华,张利朝,等.恶性肿瘤患者T细胞亚群与红细胞免疫功能的变化及其相关性分析[J].实用癌症杂志.2001.16(2):171-173.
[149]Soygur T,Beduk Y,Yaman O,et al Analysis of the peripheral blood lymphocyte subsets in patients with bladder carcinoma[J].Urology.1999,53(1):88-91.
[150]Bentdal OH,Froland SS,Bosnes V,et al.Alteration of lymphocyte subsets in blood may predict resectibility in carcinoma of cardia or oesophogus[J].Cancer Letters.1996,100:133-138.
[151]Liua Y,poona RT.Hughesb J,et al.Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma[J].Clin Immunol.2005.114:174,182.
[152]曹健,乔颖,陈大伟.胃肠道恶性肿瘤患者NK细胞和T细胞亚群的改变[J]中华肿瘤杂志.1997.19(2):133-136.
[153]金从国,王熙才,伍治平,等.癌症患者外周血T细胞亚群水平及临床意义[J]肿瘤研究与临床.2003,15(1):33-36.
[154]Cho Y,M iyamoto M,Kato K,et al.CD4+ and CI)8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma[J].Cancer Res.2003,63(7):1555-1559.
[155]鞠秀丽,孙念政,刘继玲,等.儿童急性淋巴细胞白血病患者T淋巴细胞免疫功能的研究.临床血液学杂志.2004,17(2):84-86.
[156]Skinnider BF,Mak TW.The role of cytokines in classical Hodgkin lymphoma [J].Blood.2002,99(12):4283-4297.
[157]Farag S S,VanDeusen J B,Fehniger T A et al.Biology and clinical impact of human natural killer cells[J].Int J Hematol.2003,78(1):7-17.
[158]Kuhista B,Trieh K,Blahovee H et al.Hyperthermia increases the susceptibility of chondro anti teosareoma cells to natural killer cell mediated lysis[J]Anticancer Res.2002,22(2A):789-792.
[159]Seki S,Habu Y,Kawamura T,et al.The liver as a crucial organ in the first line host defense:the roles of Kupffer cells,NK cell and NK1,1Ag+T cell in T helper 1 immune responses[J].Immunological Rev.2000,174:35-46.
[160]Mark JS.Kevin YRT.Shayna EAS,et al.Defferential tumor surveillance by NK and NKT cells[J].J Exp Med,2000,101:661,668.
[161]周启明,吴沛宏.T淋巴细胞亚群及NK细胞变化与原发性肝癌预后的关系[J].介入放射学杂志.2005,14(6):635-637.
[162]胡挺,张顺,徐焕龙.鼻咽癌患者外周血T淋巴细胞亚群和NK细胞检测.中国肿瘤.2006,15(3):195-196.
[163]邢爱民,孙玉凤,陈玉凤.肺癌患者外周血T淋巴细胞亚群变化及其临床意义[J].肿瘤学杂志.2004,10(3):173-174.
[164]陈文宽,宋明,陈福进,等.喉咽鳞癌患者外周血T淋巴细胞亚群和NK细胞活性分析[J].癌症.2006,25(10):1300-1302.
[165]Kuss I,Hathaway B,Ferris R L,et al.Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease[J].Adv Otorhinolaryngol.2005,7(62):161-172.
[166]赵代伟,叶晖,王南鹏,等.甲状腺癌患者外周血T细胞亚群和NK细胞活性动态变化及临床意义[J].山东医药.2008,48(26):78-79.
[167]李惠萍,李世荣.卵巢恶性肿瘤患者外周血T淋巴细胞亚群NK细胞活性检测的临床意义[J].中华临床新医学.2002,2(1):13-14.
[168]秦晓云,薛际航.脑肿瘤患者外围血T淋巴细胞亚群测定分析.中国误诊学杂志.2008,8(30):7349-7350.
[169]梁索源,李巧霞,张超,等.食管癌患者红细胞免疫功能和T细胞亚群、自然杀伤细胞活性的研究[J].临床荟萃.2008,23(16):1184-1185.
[170]宁军,龚浩.中晚期肿瘤患者T淋巴细胞和NK细胞检测的临床意义[J].实用全科医学,2007,5(7):587-588.
[171]邬露丹,徐炜峰,熊逸群.恶性肿瘤患者淋巴细胞亚群的测定及与癌胚抗原的关系[J].实验与检验医学.2008,26(1):57-58.
[172]何立丽,孙桂芝.孙桂芝治疗恶性肿瘤经验撷微[J].北京中医药.2008,27(12):932-933.
[173]贾文娟,邢秀玲,贾英杰,等.扶正合剂改善乳腺癌患者化疗副作用的临床观察[J].河北中医.2008,30(11):1141-1142,1148.
[174]汤桂梅,赵彦南,陈坤.芪甲扶正胶囊辅助化疗治疗中晚期非小细胞肺癌的临床观察[J].河北中医.2008,30(10):1025-1026.
[175]韩旭.扶正固本治疗癌症放化疗后白细胞减少症36例[J].四川中医.2007,25(10):69-70.
[176]熊墨年.略谈运用扶正抑癌治疗肿瘤的几点体会.实用中西医结合临床.2008,8(5):45-46.
[177]刘嘉湘.恶性肿瘤的中医药治疗—阴阳平衡与扶正治癌理论在癌症治疗中的应用[J].江苏中医药.2008,40(9):1-2.
[178]曾英.肿瘤从虚论治.吉林中医药.2008,28(1):3-4.
[179]华海清.扶正培本药物治疗恶性肿瘤的现代研究[J].中国中药杂志.2008,33(9):1094-1097.
[180]李万辉.中医扶正疗法在恶性肿瘤姑息治疗中的地位[J].北京中医药.2008,27(2):112-114.
[181]杜娟.中药抗肿瘤免疫的研究进展[J].中医药临床杂志.2004,16(5):507-509.
[182]Arlen PM,Gulley JL,Todd N,et al.Anti-androgen,vaccine and combination therapy in patients with nonmetastratic hormone refractory prostate cancer[J]. J Urol.2005,174(2):539-546.
[183]王宇岭,高远,殷红,等.参芪扶正注射液对恶性胃肠道肿瘤患者免疫功能的影响[J].中药新药与临床药理.2008,19(6):506-507.
[184]朱琨,李康,党诚学.参芪扶正注射液对乳腺癌术后行CEF方案化疗患者免疫功能的影响[J].现代肿瘤医学.2008,16(10):1712-1714.
[185]林梅英,关莹,侯恩存.黄芪注射液对化疗副作用的拮抗作用的临床观察[J].广州中医药大学学报.2006,23(2):127-129.
[186]罗晶,郭焱.人参养荣汤对小鼠免疫功能的调节[J].中国现代医学杂志.2002,12(5):27-28.
[187]马红,沈继泽.金匮肾气丸免疫调节作用的实验研究[J].中药药理与临床.2000,16(6):5-6.
[188]梁超,张胜华,蔡照弟,等.早期肠内应用四君子汤对消化道肿瘤术后患者免疫功能的影响[J].中国中西医结合杂志.2005,25(12):1070-1073.
[189]白广德,练祖平,黄丁平,等.八珍汤加味配合西医治疗对中晚期肝癌患者生存质量及免疫功能的影响[J].四川中医.2008,26(4):73-75.
[190]曹志然,韩艳梅,戎瑞雪,等.十全大补汤对移植乳腺癌小鼠免疫抑瘤作用的实验研究[J].时珍国医国药.2007,18(4):F0003-F0004.
[191]徐勇,卢杏生.生脉注射液对胃癌术后免疫功能的影响[J].辽宁中医杂志.2008,35(10):1451-1453.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |